Search results for "Aciclovir"

showing 9 items of 9 documents

Acyclovir treatment in 2 patients with benign trigeminal sensory neuropathy

2001

AdultMaleHerpesvirus 3 Humanmedicine.medical_specialtymedicine.medical_treatmentAcyclovirAdministration OralNeurological disorderAntibodies ViralAntiviral AgentsHypesthesiamedicineHumansSimplexvirusAciclovirTrigeminal nerveChemotherapybusiness.industryAcyclic nucleosideHypoesthesiamedicine.diseaseDermatologySurgeryPeripheral neuropathyOtorhinolaryngologyTrigeminal Nerve DiseasesImmunoglobulin GSensory neuropathyFemaleSurgeryOral Surgerymedicine.symptombusinessFollow-Up Studiesmedicine.drugJournal of Oral and Maxillofacial Surgery
researchProduct

Severe herpes simplex virus type-I infections after dental procedures

2010

Background: Recurrences of herpes labialis (RHL) may be triggered by systemic factors, including stress, menses, and fever. Local stimuli, such as lip injury or sunlight exposure are also associated to RHL. Dental extraction has also been reported as triggering event. Case reports: Seven otherwise healthy patients are presented with severe and extensive RHL occurring about 2-3 days after dental extraction under local anaesthesia. Immunohistochemistry on smears and immunofluorescence on cell culture identified herpes simplex virus type I (HSV-I). Five patients reported more severe prodromal signs than usual. Although all the patients suffered from RHL, none had previously experienced RHL aft…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentmedicine.disease_causeSeverity of Illness IndexYoung AdultSeverity of illnessHumansMedicineYoung adultGeneral DentistryHerpes Labialisbusiness.industryIncidence (epidemiology)Herpes SimplexMiddle Aged:CIENCIAS MÉDICAS [UNESCO]DermatologySurgeryValaciclovirHerpes simplex virusOtorhinolaryngologyDental extractionTooth ExtractionUNESCO::CIENCIAS MÉDICASFemaleSurgerybusinessComplicationmedicine.drug
researchProduct

Transfer of aciclovir from plasma to human breast milk.

2011

Aciclovir (CAS 59277-89-3) is frequently used in herpes simplex virus diseases, but administration to lactating women occurs only rarely. Therefore, information about the pharmacokinetics of aciclovir in human breast milk is limited. The concentration in breast milk is 2 to 3 fold increased compared to plasma. The reason for this increase is unknown until now. An active transport mechanism has been assumed. The aim of this study was to prove whether the higher concentration of aciclovir in human breast milk is due to only a passive transfer. Two chambers separated by a semipermeable membrane were used. The first chamber contained plasma with aciclovir, the second chamber breast milk without…

AdultMilk HumanChemistryAcyclic nucleosidevirus diseasesHuman metabolismAcyclovirPharmacologyBreast milkmedicine.disease_causeAntiviral AgentsDiffusionHerpes simplex virusPharmacokineticsDrug DiscoveryBlood plasmaImmunologymedicineHumansFemaleAciclovirHuman breast milkmedicine.drugArzneimittel-Forschung
researchProduct

Combined therapy with acyclovir and adenosine arabinoside in herpes simplex encephalitis.

1987

We report a case of herpes simplex encephalitis (HSE) with initial coma and severe left-sided hemiparesis in which combined treatment with adenine arabinoside and acyclovir was followed by complete recovery. This favorable result is discussed in view of the literature of HSE treatment including experimental studies on antiviral activity of both drugs. Combined treatment may be useful in severe cases of HSE.

Adultmedicine.medical_treatmentAcyclovirmedicineHumansAciclovirVidarabineComaChemotherapybusiness.industryHerpes Simplexmedicine.diseaseVirologyAdenosineHemiparesisNeurologyEncephalitisDrug Therapy CombinationFemaleNeurology (clinical)Viral diseasemedicine.symptombusinessTomography X-Ray ComputedEncephalitisVidarabinemedicine.drugEuropean neurology
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Aciclovir

2008

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing (biowaiver) for the approval of immediate release (IR) solid oral dosage forms containing aciclovir are reviewed. Aciclovir therapeutic use and therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA) studies were also taken into consideration in order to ascertain whether a biowaiver can be recommended. According to the Biopharmaceutics Classification System (BCS) and considering tablet strengths up to 400 mg, aciclovir would be BCS Class III. However, in some countries also 800 mg tablets are available which …

Drugbusiness.industrymedia_common.quotation_subjectAcyclovirAdministration OralBiological Availabilityvirus diseasesPharmaceutical ScienceExcipientPharmacologyBioequivalenceBiopharmaceutics Classification SystemAntiviral AgentsDosage formTherapeutic EquivalencyPharmacokineticsmedicineRegulatory scienceAciclovirbusinessmedicine.drugmedia_commonJournal of Pharmaceutical Sciences
researchProduct

Comparative analysis of DNA breakage, chromosomal aberrations and apoptosis induced by the anti-herpes purine nucleoside analogues aciclovir, gancicl…

2002

Nucleoside analogues have been used in antiviral therapy and suicide cancer gene therapy. Therefore, it is of importance to compare their potential cytotoxic and genotoxic action. Using metabolically competent CHO cells expressing the thymidine kinase gene of herpes simplex virus type 1 (CHO-HSVtk cells) as a model system, the induction of DNA breaks was compared with the induction of structural chromosomal aberrations and apoptosis/necrosis after exposure to the anti-herpes nucleoside analogues aciclovir (ACV), ganciclovir (GCV) and penciclovir (PCV). After continuous treatment of CHO-HSVtk cells with the drugs, LD(10) in a colony-forming assay was 50, 0.5 and 1 microM for ACV, GCV and PCV…

GanciclovirGuanineDNA damagevirusesHealth Toxicology and MutagenesisAcyclovirApoptosisCHO CellsBiologymedicine.disease_causeAntiviral AgentsThymidine KinaseChromosomesColony-Forming Units AssayNecrosisCricetulusCricetinaeGeneticsmedicineCytotoxic T cellAnimalsSimplexvirusAciclovirEnzyme InhibitorsMolecular BiologyGanciclovirChromosome AberrationsDNAMolecular biologyHerpes simplex virusApoptosisPenciclovirNucleosidemedicine.drugDNA DamageMutation research
researchProduct

Successful treatment of HSV encephalitis during pregnancy.

1989

A propos d'une femme presentant une grossesse de 23 semaines. Description des signes cliniques et electroencephalographiques. Les effets de l'aciclovir sur l'encephalite et sur l'evolution de la grossesse sont etudies

GynecologyAdultPregnancymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentAcyclovirHerpes Simplexmedicine.diseasePregnancyImmunologymedicineGestationEncephalitisHumansFemaleNeurology (clinical)AciclovirHsv encephalitisPregnancy Complications InfectiousbusinessEncephalitismedicine.drugNeurology
researchProduct

Failure of acyclovir to enhance the antiviral effect of α lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B

1992

Serum HBeAg levels and HBe-seroconversion were investigated in patients with chronic HBeAg-positive hepatitis who were randomized to receive either alpha lymphoblastoid interferon (5 megaunits subcutaneously daily for 16 weeks) plus acyclovir (2 g intravenously daily during weeks 1 and 2 and weeks 9 and 10) (n = 49) or no treatment (n = 48). HBeAg levels in serial dilutions of patient serum were assessed quantitatively by radioimmunoassay and compared with the values found for negative control serum. One year after the start of therapy 44 treated patients and 43 control patients were available for follow-up. A complete response (HBe-seroconversion) occurred in 11 treated patients (25%) and …

HepatitisChemotherapymedicine.medical_specialtyHepatologyCombination therapybusiness.industrymedicine.medical_treatmentvirus diseasesAlpha interferonmedicine.diseaseGastroenterologydigestive system diseasesHBeAgInternal medicineImmunologymedicineAciclovirSeroconversionbusinessInterferon alfamedicine.drugJournal of Hepatology
researchProduct

PROFILASSI UNIVERSALE CONTRO IL CITOMEGALOVIRUS CON VALGANCICLOVIR NEI SOGGETTI RICEVENTI TRAPIANTO DI RENE

2009

Introduzione: In questo studio descriviamo l’incidenza di infezione da citomegalovirus (CMV) e della malattia da CMV dopo profilassi universale contro il CMV con valganciclovir orale in un gruppo di pazienti riceventi trapianto di rene trattati in differenti studi clinici randomizzato con un potente regime immunosoppressivo. Metodi: Da Maggio 2000 a Ottobre 2008, 622 riceventi (R) il primo trapianto di rene da donatore (D) vivente e cadavere furono randomizzato in differenti protocolli. Questo report descrive in dettaglio l’incidenza dell’infezione e della malattia da CMV. Tutti i pazienti furono trattati con ganciclovir® endovenoso per 3 giorni, seguito dalla somministrazione orale quotidi…

Settore MED/18 - Chirurgia GeneraleCitomegalovirus trapianto di rene vangaciclovir
researchProduct